Episode 20- Regulations on artificial intelligence- impact on drug discovery

Our speakers:

Sheraz Gul

Sheraz is a drug discovery expert with experience in academia (University of London), industry (GSK) & the largest European applied research organisation (Fraunhofer Institute).

Extensive insight and consulting experience in the pre-clinical drug discovery domain across the common therapeutic areas with particular focus on target validation, biological reagent design, assay development, screening, Hit validation and their progression to Lead and Clinical Candidate molecules. Led multiple collaborations and ensured milestones were met in accord with Target Product Profiles, project cascades and budgets. Managed resources and supervised teams up to post-doc level. Advised drug discovery companies, Member of Editorial, Review and Conference Organising Committees. Currently hold a visiting academic position at NUI-Galway, Ireland and scientific co-founder of Transcriptogen Ltd.

High quality science communication through presentations at conferences, co-author of >70 peer-reviewed papers, the Enzyme Assays: Essential Data handbook and founding editor of Drug Target Review with regular contributions. Organised 50 global drug discovery consultancy workshops & trained >975 scientists.

Dr Aaron Daughtery

Most recently Vice President of Discovery at Aria Pharmaceuticals, Aaron led the design and building of Aria’s AI drug discovery platform as well as the Discovery team’s efforts to discover potential treatments across a wide range of diseases. Aaron earned his PhD in Genetics from Stanford University, US. Prior to his time at Stanford, Aaron was a Fulbright Scholar and received his Bachelor of Science in Biology from the University of Richmond, US.